Senegal's ‘schools for husbands' aim to shift gender roles and keep mothers from dying
DAKAR, Senegal (AP) — On a recent evening in Senegal 's capital of Dakar, an imam named Ibrahima Diane explained to a group of men why they should be more involved in household chores.
'The Prophet himself says a man who does not help support his wife and children is not a good Muslim,' the 53-year-old said, as he described bathing his baby and helping his wife with other duties.
Some of the 14 men chuckled, not quite sold. Others applauded.
Diane was taking part in a 'school for husbands,' a United Nations-backed initiative where respected male community members learn about 'positive masculinity' in health and social issues and promote them in their communities.
In Senegal, as in many other West African countries with large rural or conservative populations, men often have the final say in major household decisions, including ones related to health.
Women may need their permission for life-changing decisions on accessing family planning or other reproductive health services, along with hospital deliveries or prenatal care.
Following his sessions at the school for husbands, Diane regularly holds sermons during Friday prayers where he discusses issues around gender and reproductive health, from gender-based violence to fighting stigma around HIV.
'Many women appreciate my sermons," he said. 'They say their husbands' behavior changed since they attended them." He said some men have told him the sermons inspired them to become more caring husbands and fathers.
Habib Diallo, a 60-year-old former army commando, said attending the sermons and discussions with the imam taught him about the risks of home births.
'When my son's wife was pregnant, I encouraged him to take her to the hospital for the delivery,' Diallo said. 'At first, he was hesitant. He worried about the cost and didn't trust the hospital. But when I explained how much safer it would be for both his wife and the baby, he agreed.'
No more barking orders
The program launched in Senegal in 2011 but in recent years has caught the attention of the Ministry of Women, Family, Gender and Child Protection, which sees it an effective strategy to combat maternal and infant mortality.
'Without men's involvement, attitudes around maternal health won't change," said 54-year-old Aida Diouf, a female health worker who collaborates with the program. Many husbands prefer their wives not be treated by male health workers, she said.
The classes for husbands follow similar efforts in other African countries, particularly Niger, Togo, and Burkina Faso, where the United Nations Population Fund says it improved women's access to reproductive health services by increasing male involvement, growing the use of contraceptives by both men and women and expanding access to prenatal care and skilled birth attendants.
Discussions for men also have focused on girls' rights, equality and the harmful effects of female genital mutilation.
The program now operates over 20 schools in Senegal, and over 300 men have been trained.
In some communities, men who once enforced patriarchal norms now promote gender equality, which has led to a reduction in the number of forced marriages and more acceptance of family planning, according to Senegal's ministry of gender.
Men join the groups after being recruited based on trust, leadership and commitment. Candidates must be married, respected locally and supportive of women's health and rights.
After training, the men act as peer educators, visiting homes and hosting informal talks.
'My husband used to not do much around the house, just bark orders. Now he actually cooks and helps out with daily tasks,' said Khary Ndeye, 52.
Still too many dying in childbirth
While maternal and infant deaths in Senegal have declined over the past decade, experts say it still has a long way to go. It recorded 237 maternal deaths for every 100,000 live births in 2023, while 21 newborns out of every 1,000 died within their first month. The U.N. globally wants to reduce maternal deaths to 70 deaths per 100,000 live births and newborn deaths to under 12 per 1,000 by 2030.
One key problem was that many women have been giving birth at home, said El Hadj Malick, one of the Senegal program's coordinators.
'By educating men about the importance of supporting their wives during pregnancy, taking them to the hospital and helping with domestic work at home, you're protecting people's health,' Malick said.
He said he still experiences difficulty changing mindsets on some issues.
'When we just talk to them about gender, there is sometimes tension because it's seen as something abstract or even foreign,' Malick said. Some men mistakenly believe such talk will promote LGBTQ+ issues, which remain largely taboo in much of West Africa.
"But when we focus on women's right to be healthy, it puts a human face on the concept and its becomes universal,' Malick said.
___
For more on Africa and development: https://apnews.com/hub/africa-pulse
___
The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
35 minutes ago
- Business Wire
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 utilizes the Signatera ctDNA test in patients with MIBC to detect molecular residual disease (MRD) in the bloodstream after surgery and predict who will benefit from adjuvant treatment with the cancer immunotherapy atezolizumab (Tecentriq®). Approximately 760 patients were enrolled in the surveillance phase of the trial and underwent serial Signatera testing for up to 12 months post surgery. Patients were randomized to treatment with atezolizumab or placebo if they tested Signatera-positive and remained free of cancer recurrence on imaging with treatment administered every 4 weeks for 12 cycles or up to one year. Patients who consistently tested Signatera-negative were not randomized to treatment but continued to be followed up with radiographic imaging and ctDNA MRD testing. Topline results from IMvigor011 demonstrated a statistically significant and clinically meaningful improvement in disease-free survival and overall survival for Signatera-positive patients treated with atezolizumab. Natera expects trial data to be presented at an upcoming medical conference. 'The results of IMvigor011 are very significant, opening the door for a new treatment paradigm for bladder cancer patients who are positive for recurrence on a molecular level but have no evidence of disease on imaging,' said Professor Thomas Powles, MBBS, MRCP, M.D., lead principal investigator of the study; Barts Cancer Institute QMUL. 'We look forward to presenting the positive results later this year.' 'Importantly, IMvigor011 could change how resectable bladder cancer is managed for the tens of thousands of patients diagnosed with MIBC each year,' said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. Natera will finalize its premarket approval application to the U.S. Food and Drug Administration for Signatera as a companion diagnostic for the selection of patients with MIBC to be treated with atezolizumab after cystectomy. In addition to the topline result released today, a preliminary analysis of Signatera-negative patients from IMvigor011 was presented at the European Association of Urology in April 2024. The data highlighted that post-operative patients who remain Signatera-negative on serial testing had excellent outcomes without adjuvant treatment. The analysis showed that 171 patients who remained Signatera-negative during the surveillance window had overall survival rates of 100% at 12 months and 98% at 18 months, and disease-free survival rates of 92% at 12 months and 88% at 18 months after surgery. Notes Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. *ctDNA MRD = circulating tumor DNA molecular residual disease About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and

Associated Press
an hour ago
- Associated Press
Bupa Hong Kong Connects More Customers to Flexible and Affordable Outpatient Care with Blua Health Pass
Blua Health Pass promotes everyday wellness by making outpatient care more accessible across digital and in-person touchpoints, under Bupa's commitment to Together for Your Health HONG KONG SAR - Media OutReach Newswire - 18 August 2025 - To more effectively meet the evolving needs of healthcare customers in Hong Kong, Bupa Hong Kong is now launching Blua Health Pass, a subscription-based outpatient healthcare solution designed to deliver accessible local care. This programme empowers individuals to take control of their health with ease, flexibility and affordability. Bupa Hong Kong Connects More Customers to Flexible and Affordable Outpatient Care with Blua Health Pass With plans starting at just HK$250, Blua Health Pass connects customers to preventative care that meets the everyday wellness needs of today's workforce and health-conscious individuals. Developed to provide greater choice, Blua Health Pass offers seamless access to a wide range of outpatient services across digital and physical touchpoints—making it even more convenient to book appointments with general practitioners, specialists, Traditional Chinese Medical practitioners and physiotherapists. Customers can also track health progress, complete health missions and receive wellness recommendations available through the Blua Health app. Blua Health, Hong Kong's leading one-stop AI-powered mobile app, offers a range of digitally-enabled services including video consultations and ePharmacy¹, rewards for health missions, insurance management², and claims and other results review. Three New Plans to Support Everyday Healthcare Needs Blua Health Pass³ offers three levels of protection, with exclusive rates of up to 67% on standard service fees at around 380 service points and more than 20 specialties across Hong Kong. Customers can take advantage of priority eBooking on the Blua Health App for less wait time, AI-powered health assessments, digital prescription ordering and healthy living rewards. The three plans include: Yuman Chan, General Manager of Bupa Insurance Business in Hong Kong, said, 'Blua Health Pass helps to fill the outpatient medical needs for individuals without comprehensive insurance: whether they are freelancing, working for a startup, retired, or simply seeking an easier and more affordable way to access everyday care. Members can also stay in control of their healthcare management anytime, anywhere, and fully harness technology to integrate health into everyday life whilst making preventative care more affordable.' Sign up for your preferred Blua Health Pass on Blua Health App today. Click this link to subscribe in just five minutes and begin enjoying accessible local care, priority in outpatient appointment bookings and exclusive rates: ¹Video consultation and ePharmacy features are provided by our medical service provider. ²Insurance management services are offered through myBupa feature of Blua Health. myBupa is offered, distributed and operated by Bupa (Asia) Limited. Blua Health is not a licensed insurance agent of Bupa (Asia) Limited, nor does it represent Bupa to conduct any insurance activities. The fact that Blua Health provides myBupa feature does not constitute and should not be construed as Blua Health conducting any Regulated Activities as defined by the Insurance Ordinance, Chapter 41 of the Laws of Hong Kong, or any insurance activities. ³Blua Health Pass is a subscription-based membership scheme offered, distributed and operated by Blua (Asia) Services Limited, a company registered in Hong Kong under the Bupa Group. Blua Health Pass is not an insurance product. Terms and conditions apply. Please refer to our product leaflet for more details. Hashtag: #Bupa #BupaHongKong #保柏 #保柏香港 #BluaHealthPass #BluaHealth通行證 #healthcare #日常保健 The issuer is solely responsible for the content of this announcement. Bupa – An international health insurance specialist Established in 1947, Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 60 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. Bupa has businesses around the world, principally in Australia, the UK, Spain, Poland, Chile, Hong Kong SAR, India, Türkiye, Brazil, Mexico and New Zealand. We also have associate businesses in Saudi Arabia. Bupa has been a health insurance specialist in Hong Kong since 1976, offering one-stop solutions across domestic and international health insurance, and healthcare services. Our comprehensive medical insurance schemes are tailored to meet individual needs, and we provide health solutions for companies of all sizes. We also have a team of registered nurses, health management professionals, and doctors who provide various expert healthcare support. Our healthcare provision arm, Quality HealthCare Medical Services (QHMS), became part of Bupa in October 2013. QHMS offers Western Medicine, Traditional Chinese Medicine, Diagnostics & Imaging, Dental, Physiotherapy, Mental Health and Wellness services via a network of over 1,650 provider service points in Hong Kong. For more information, visit


Medscape
3 hours ago
- Medscape
Study: How Do Young Adolescents Express Gender Identity?
TOPLINE: A study of just over 10,000 US kids and teens aged 11-15 years found that 1.02% of adolescents identify as transgender; approximately 8.2% who were assigned female gender at birth and 1.3% assigned male gender at birth reported sometimes feeling like the other gender. METHODOLOGY: The study included 10,089 adolescents aged 11-15 years (mean age, 12.91 years) from 21 study sites across the US, each assessed through the Adolescent Brain Cognitive Development Study Youth Gender Survey between 2019 and 2021. Statistical analysis was performed over a period beginning in June 2024 and ending in March 2025. Researchers evaluated six gender constructs: two continuous measures (felt gender, self-described placement on the gender spectrum), two ordinal measures (level of dissatisfaction with one's gender and gender expression), and two categorical measures (felt gender category and transgender identity). TAKEAWAY: A little over 1% of kids and teens identified as transgender (1.02%; 95% CI, 0.81%-1.27%), with 1.1% (95% CI, 0.9%-1.4%) responding 'maybe' to the transgender identity question. Gender diversity varied by birth assignment, with 8.2% of adolescents assigned female gender at birth expressing feelings of being a boy and 1.3% of those assigned male gender at birth expressing feelings of being a girl. Most adolescents identified with the gender they were assigned at birth, with 51.4% of those assigned male gender at birth identifying as boys and 45.7% of those assigned female gender at birth identifying as girls. IN PRACTICE: 'Our study highlights the complexity of gender within early adolescents, especially as it relates to the way early adolescents are asked about gender and their understanding of the language used,' the study authors wrote. 'The use of multidimensional measurements of gender will aid in the development of inclusive policies and public health guidance that meet the needs of gender-diverse early adolescents.' SOURCE: The study was led by Jason M. Nagata, MD, MSc, Department of Pediatrics, University of California, San Francisco. It was published online on August 11 in JAMA Pediatrics. LIMITATIONS: A cross-sectional method and self-reported data were used, which may have affected the accuracy of the results. DISCLOSURES: Various study authors reported receiving grants from National Institutes of Health during the conduct of the study. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.